Key Highlights

  • Revenue was USD 13.49 million against an estimate of USD 14.82 million.
  • Loss per share was USD 0.08 against an estimate of a USD 0.17 loss.
  • Six patients were treated in the quarter, bringing the launch total to 15.
  • Abeona announced the Acquisition of ABO-801, formerly APT-1011, from Ellodi Pharmaceuticals.

Abeona Therapeutics (NASDAQ:ABEO) reported third quarter 2026 Revenue of USD 13.49 million, against an estimate of USD 14.82 million. The loss per share was USD 0.08, compared with an estimate of a USD 0.17 loss. The revenue reflects commercial sales of ZEVASKYN, an autologous cell-based gene therapy for wounds in adults and children with recessive dystrophic epidermolysis bullosa.

The company's management said ZEVASKYN net revenue of USD 13.5 million was an 18% increase from the prior quarter. The call coincided with the announcement of the acquisition of APT-1011, now ABO-801, from Ellodi Pharmaceuticals L.P., which the filing lists as closing on November 9, 2026.

ZEVASKYN Launch Progress

Six patients were treated with ZEVASKYN in the quarter, bringing the total treated since launch to 15. Revenue was recognized for five of the six treatments. Management said revenue was not recognized for one treatment because the associated batch did not meet specification for the pan-CK identity assay.

Two activated qualified treatment centers, CHOP and UTMB, treated their first patients in the quarter. That brought the number of treatment centers with ZEVASKYN experience to four. The filing notes that the centers are under no obligation to use ZEVASKYN, and the company has no contractual right to payment until final quality inspection and transfer of control are completed.

Expenses and Other Income

Cost of sales was USD 5.7 million and mainly includes costs from the commercial sale of ZEVASKYN, including royalties owed to licensor Stanford. Research and Development expenses were USD 3.7 million, against USD 4.2 million a year earlier. Selling, general and administrative expenses were USD 17.1 million, against USD 19.3 million.

Interest income was USD 2.3 million, compared with USD 1.7 million, and interest expense was USD 0.6 million, compared with USD 0.9 million. A non-cash gain on the change in Fair Value of Warrant liabilities was USD 6.5 million, compared with a USD 2.8 million gain a year earlier. The filing attributes the gain to a decrease in the company's stock price over the quarter and a shorter remaining term for the warrants.

Liquidity and Pipeline

The company concluded that its Capital resources are sufficient to fund operating expenses and Capital Expenditure for at least the next 12 months from the issuance date of the financial statements. Its development portfolio includes ABO-701, a PSMA-targeted engineered T-cell therapy for solid tumors, and its cell and gene therapy Manufacturing Facility in Cleveland, Ohio produces ZEVASKYN for commercial use.

The ABO-801 acquisition is intended to broaden the company's opportunities beyond ZEVASKYN. Management said ZEVASKYN remains the foundation of the Business and its immediate operating priority.

Abeona Therapeutics Q3 2026 Earnings: Key Takeaways

Abeona Therapeutics reported third quarter 2026 revenue of USD 13.49 million and a loss per share of USD 0.08. Six patients were treated in the quarter and 15 since launch, with four treatment centers now experienced with the therapy. The company also announced the acquisition of ABO-801 and reported that its capital resources cover at least the next 12 months.